🇺🇸 FDA

Company profile · Sponsor

MAIA

MAIA Biotechnology

MAIA · NYSE biotech CHICAGO, IL, USA
Pipeline
8
Drugs
7
Patents
8

Quick answer

MAIA (MAIA) is a biotech company. headquartered in CHICAGO, IL, USA. listed on NYSE. NovaPharmaNews links 8 pipeline programs, 7 drugs, and 8 patents to this profile..

Company facts

Ticker MAIA
Exchange NYSE
Company type biotech
Headquarters CHICAGO, IL, USA
SEC CIK 0001878313

Pipeline (8)

Search pipeline →

  1. 12-Valent Pneumococcal Conjugate Vaccine

    MAIA

    Pneumococcal Vaccines

    phase 3 mab active

    1 trial

  2. 6-Thio-2'-Deoxyguanosine

    MAIA

    Carcinoma, Non-Small-Cell Lung

    phase 3 small molecule active

    2 trials

  3. LIBTAYO 350 mg concentrate for solution for infusion., Vinorelbine 10 mg/ml concentrate for solution for infusion, TAXOTERE 20 mg/0.5 ml concentrate and solvent for solution for infusion, THIO, Gemcitabine 1 g Powder for Solution for Infusion

    MAIA

    Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  4. LIBTAYO 350 mg concentrate for solution for infusion., THIO

    MAIA

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  5. etrasimod

    MAIA

    Pouchitis

    phase 2 small molecule active

    1 trial

  6. Fecal Microbiota Transplant (FMT)

    MAIA

    Chronic Pouchitis

    phase 1 small molecule active

    1 trial

  7. ateganosine

    MAIA

    Resectable Hepatocellular Carcinoma

    phase 1 small molecule active

    1 trial

  8. Blood ponction

    MAIA

    Alzheimer Blood Biomarkers

    other active

    1 trial

Drugs (7)

Search drugs →

  1. baclofen

    LIORESAL

    INTRATHECAL approved

  2. bivalirudin

    ANGIOX

    INJECTION approved

    B01AE06

  3. bortezomib

    BORTEZOMIB ACCORD

    INJECTION approved

    L01XG01

  4. daptomycin

    CUBICIN

    INTRAVENOUS approved

    J01XX09

  5. levothyroxine sodium

    LEVOTHYROXINE SODIUM

    ORAL approved

  6. sincalide

    SINCALIDE

    INTRAVENOUS approved

  7. sodium benzoate

    PROHIPPUR

    ORAL approved

    A16AX11

Patents (8)

Search patents →

  1. US 12005069

    Bortezomib compositions

    Expires Mon Jun 06 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11992514

    Ready-to-use bivalirudin compositions

    Expires Mon May 23 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11918622

    Ready-to-use bivalirudin compositions

    Expires Mon Feb 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11903993

    Ready-to-use bivalirudin compositions

    Expires Mon Feb 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11752164

    Bortezomib compositions

    Expires Mon Sep 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11737983

    Storage stable sincalide formulations

    Expires Mon Aug 24 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11679119

    Bortezomib compositions

    Expires Mon Jun 15 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11672813

    Bortezomib compositions

    Expires Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is MAIA?

MAIA (MAIA) is a biotech company. headquartered in CHICAGO, IL, USA. listed on NYSE. NovaPharmaNews links 8 pipeline programs, 7 drugs, and 8 patents to this profile..

What pipeline programs does MAIA sponsor?

We track 8 ClinicalTrials.gov-linked programs for MAIA, including 12-Valent Pneumococcal Conjugate Vaccine and 7 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does MAIA company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.